Cytos Biotechnology Ltd appoints Chief Executive Officer
Cytos Biotechnology Ltd announced the appointment of Dr. Christian Itin as Chief Executive Officer. As announced on 29 May 2012, the Board will propose to the Company’s shareholders that Dr. Itin be elected as member of the Board, and it is intended that he will succeed Dr. Hecht as Chairman of the Board of Directors as of an extraordinary shareholders meeting scheduled to take place in November 2012. Dr. Hecht will step down from the Cytos Board at this meeting.
Dr. Itin (age 48 yrs.) is the former President and Chief Executive Officer of Micromet Inc., a previously Nasdaq-listed biopharmaceutical company, with headquarters in the USA and an R&D center in Germany. Dr. Itin led Micromet as CEO from 2004 until Micromet’s acquisition by Amgen for $1.2 billion in cash in March 2012. In total he spent 13 years in senior management roles at Micromet. Prior to joining Micromet in 1999, Dr. Itin co-founded Zyomyx, Inc., a protein chip company based in Hayward, CA, USA.
Dr. Itin received a diploma in biology and a Ph.D. in cell biology from the University of Basel. In addition, he performed post-doctoral research at the Biocenter of Basel University and at the Stanford University School of Medicine.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.